← All trials
NCT04121403
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2019
- Primary completion
- Jul 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 264
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OsloLead sponsor
- University of OsloOverall official - principal investigator
- University of OsloStudy chair
- University of OsloReponsible party - principal investigator
- Vestre Viken Ringerike SykehusCollaborator
- University of GothenburgCollaborator
- University of StavangerCollaborator
- University Hospital of North NorwayCollaborator
- University of OsloCollaborator
- Sykehuset OstfoldCollaborator
- Sykehuset i Vestfold HFCollaborator
- Sorlandet Hospital HFCollaborator
- Telemark Hospital TrustCollaborator
- Sykehuset Innlandet HFCollaborator
- Helse FordeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.